Boehringer and Zealand want to outperform Novo and are comparing their obesity treatment to semaglutid
Boehringer Ingelheim and Zealand Pharma are collaborating to develop an obesity treatment, which they are comparing to semaglutid in a new phase II study. The treatment is a potential future winner, says Zealand Pharma.
BY KEVIN GRØNNEMANN, TRANSLATED BY CATHERINE BRETT
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.